Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma

被引：16
|
作者：
Graham, Charlotte Elizabeth [1 ,2 ]
Jozwik, Agnieszka [1 ]
Quartey-Papafio, Ruby [1 ]
Ioannou, Nikolaos [1 ]
Metelo, Ana M. [1 ]
Scala, Carlo [1 ]
Dickson, Glenda [1 ]
Stewart, Orla [2 ]
Almena-Carrasco, Maria [3 ]
Peranzoni, Elisa [3 ]
Ramsay, Alan G. [1 ]
Patten, Piers E. M. [1 ,2 ]
Pertel, Thomas [4 ]
Farzaneh, Farzin [1 ]
Dupouy, Sandra [3 ]
Pepper, Andrea [5 ]
Benjamin, Reuben [1 ,2 ]
机构：
[1] Kings Coll London, Fac Life Sci & Med, Sch Canc & Pharmaceut Sci, London, England
[2] Kings Coll Hosp NHS Fdn Trust, London, England
[3] Inst Rech Int Servier, Paris, France
[4] Allogene Therapeut, San Francisco, CA USA
[5] Univ Sussex, Brighton & Sussex Med Sch, Brighton, E Sussex, England
来源：
LEUKEMIA | 2021年 / 35卷 / 12期
基金：
英国生物技术与生命科学研究理事会; 英国工程与自然科学研究理事会;
关键词：
B-CELL;
D O I：
10.1038/s41375-021-01324-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：3581 / 3584
页数：4
相关论文
共 28 条
  • [21] Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry
    Galtier, Jean
    Mesguich, Charles
    Sesques, Pierre
    Dupont, Vivien
    Bachy, Emmanuel
    Di Blasi, Roberta
    Thieblemont, Catherine
    Gastinne, Thomas
    Cartron, Guillaume
    Brisou, Gabriel
    Gros, Francois-Xavier
    Decroocq, Justine
    Morschhauser, Franck
    Rubio, Marie-Therese
    La Rochelle, Laurianne Drieu
    Le Bras, Fabien
    Carras, Sylvain
    Chauchet, Adrien
    Bay, Jacques-Olivier
    Joris, Magalie
    Loschi, Mickael
    Tanguy-Schmidt, Aline
    Marquet, Alexandra
    Camus, Vincent
    Le Gouill, Steven
    Houot, Roch
    Bouabdallah, Krimo
    HEMASPHERE, 2025, 9 (02):
  • [22] Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+lymphoma: a phase 1 study
    Grover, Natalie S.
    Hucks, George
    Riches, Marcie L.
    Ivanova, Anastasia
    Moore, Dominic
    Shea, Thomas C.
    Seegars, Mary Beth
    Armistead, Paul M.
    Kasow, Kimberly A.
    Beaven, Anne W.
    Dittus, Christopher
    Coghill, James M.
    Jamieson, Katarzyna J.
    Vincent, Benjamin G.
    Wood, William A.
    Cheng, Catherine
    Morrison, Julia Kaitlin
    West, John
    Cavallo, Tammy
    Dotti, Gianpietro
    Serody, Jonathan S.
    Savoldo, Barbara
    LANCET HAEMATOLOGY, 2024, 11 (05): : e358 - e367
  • [23] Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling
    da Silva, Diogo Gomes
    Mukherjee, Malini
    Srinivasan, Madhuwanti
    Dakhova, Olga
    Liu, Hao
    Grilley, Bambi
    Gee, Adrian P.
    Neelapu, Sattva S.
    Rooney, Cliona M.
    Heslop, Helen E.
    Savoldo, Barbara
    Dotti, Gianpietro
    Brenner, Malcolm K.
    Mamonkin, Maksim
    Ramos, Carlos A.
    BLOOD, 2016, 128 (22)
  • [24] Gene-edited allogeneic CAR19 T cells (UCART19) induce molecular remission ahead of allo-SCT in high risk pediatric patients with CD19+relapsed/refractory B-cell acute lymphoblastic leukemia
    Qasim, Waseem
    Ciocarlie, Oana
    Adams, Stuart
    Inglott, Sarah
    Murphy, Claire
    Rivat, Christine
    Wright, Gary
    Lucchini, Giovanna
    Silva, Juliana
    Rao, Kanchan
    Zinai, Amina
    Binlich, Florence
    Dupouy, Sandra
    Pauly, Jeanne
    Balandraud, Svetlana
    Simon, Flavie
    Konto, Cyril
    Bermingham, Candy
    Chiesa, Robert
    Samarasinghe, Sujith
    Hara, Havinder
    Boyle, Alayna
    Chu, Jan
    Pinner, Danielle
    Amrolia, Persis J.
    Vora, Ajay
    Rao, Anupama
    Ancliffe, Philip
    Veys, Paul
    BONE MARROW TRANSPLANTATION, 2018, 53 : 27 - 28
  • [25] A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1
    Neelapu, Sattva S.
    Locke, Frederick L.
    Bartlett, Nancy L.
    Siddiqi, Tanya
    Jacobson, Caron A.
    Westin, Jason R.
    Chavez, Julio C.
    Ghobadi, Armin
    Herrera, Alex F.
    LaCasce, Ann S.
    Bot, Adrian
    Rossi, John M.
    Jiang, Yizhou
    Aycock, Jeff S.
    Elias, Meg
    Wiezorek, Jeff
    Go, William Y.
    BLOOD, 2016, 128 (22)
  • [26] DIRECT COMPARISON OF IN VIVO FATE OF SECOND AND THIRD-GENERATION CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS IN PATIENTS WITH B CELL NON-HODGKIN LYMPHOMA (B-NHL): REVERSAL OF TOXICITY FROM TONIC SIGNALING
    da Silva, D. Gomes
    Mukherjee, M.
    Madhuwanti, S.
    Dakhova, O.
    Liu, H.
    Grilley, B.
    Gee, A.
    Neelapu, S. S.
    Rooney, C.
    Heslop, H.
    Savoldo, B.
    Dotti, G.
    Brenner, M.
    Mamonkin, M.
    Ramos, C. A.
    CYTOTHERAPY, 2017, 19 (05) : S9 - S9
  • [27] Direct Comparison of in Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL): Reversal of Toxicity From Tonic Signaling
    da Silva, Diogo Gomes
    Mukherjee, Malini
    Madhuwanti, Srinivasan
    Dakhova, Olga
    Liu, Hao
    Grilley, Bambi
    Gee, Adrian P.
    Neelapu, Sattva S.
    Rooney, Cliona M.
    Heslop, Helen E.
    Savoldo, Barbara
    Dotti, Gianpietro
    Brenner, Malcolm K.
    Mamonkin, Maksim
    Ramos, Carlos A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S40 - S41
  • [28] MAGE-A1 TARGETING TK-8001 TCR-T CELLS CURRENTLY BEING INVESTIGATED IN THE IMAG1NE PHASE 1/2 CLINICAL TRIAL DEMONSTRATE BROAD IN VITRO AND IN VIVO ANTI-TUMOUR ACTIVITY AND ARE SUPERIOR TO HUMAN-DERIVED MAGE-A1 TCRS
    Selck, C.
    Salei, N.
    Fellmer, N.
    Leisegang, M.
    Gavvovidis, I.
    Blankenstein, T.
    Sotiropoulou, P. A.
    Kieback, E.
    Jurk, M.
    Poncette, L.
    CYTOTHERAPY, 2023, 25 (06) : S250 - S251
123